Floatz logo

Monomethyl Fumarate

Recurrent Renal Cell Cancer

National Cancer Institute (NCI)Small moleculePhase 2Dormant
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Recurrent Renal Cell Cancer cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
National Cancer Institute (NCI)
Phase 3BBB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB
Fludarabine
M.D. Anderson Cancer Center
Phase 2BB
gw786034
Academic and Community Cancer Research United
Phase 3BB
INTERFERON ALFA-2B
Case Comprehensive Cancer Center
Phase 2BB

View all 36 →

Same molecule, other indications

Monomethyl Fumarate is also rated in:

Blood Stem Cell Transplant FailureDormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi AnemiaDormant
BBB
Indicative ·
74 / 100
View asset →
Refractory Anemia With Excess BlastsDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →